<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="420">
  <stage>Registered</stage>
  <submitdate>6/09/2005</submitdate>
  <approvaldate>14/09/2005</approvaldate>
  <actrnumber>ACTRN12605000393651</actrnumber>
  <trial_identification>
    <studytitle>The Pharmacogenetic and Pathological Assessment of CYP2C19 Activity in Patients with Advanced Cancer</studytitle>
    <scientifictitle>The Pharmacogenetic and Pathological Assessment of CYP2C19 Activity in Patients with Advanced Cancer as determined by omeprazole metabolism</scientifictitle>
    <utrn />
    <trialacronym>CYP2C19</trialacronym>
    <secondaryid>Clinical Trials New Zealand: CTNZ_</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2 />
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Omeprazole</interventions>
    <comparator />
    <control>Historical</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary aim of this exploratory study is to determine whether advanced cancer results in a decreased functional activity of CYP2C19, independent of genotype, as assessed by metabolism of a single dose of omeprazole</outcome>
      <timepoint>At 2 hours post administration</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine whether decreased CYP2C19 function correlates with markers of disease severity as determined by circulating inflammatory cytokines (IL1, IL6 &amp; TNF-Î±) and a marker of acute phase response, C-reactive protein.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with advanced cancer who last received cytotoxic or hormonal therapy for their cancer more than four weeks ago and who are being considered for a new line of therapy for disease progression or inadequate response to prior therapy; adequate renal and liver function; Patients must be able to provide informed consent </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients receiving medication which is either a CYP2C19 inhibitor or inducer.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Bio-availability</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>29/08/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Cancer Trials New Zealand</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Cancer Society New Zealand</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>-</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Nicole McCarthy</name>
      <address>Discipline of Oncology
Faculty of Medical &amp; Health Sciences
University of Auckland
Private Bag 92019
Auckland</address>
      <phone>+64 9 3737599</phone>
      <fax>+64 9 3737927</fax>
      <email>n.mccarthy@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Michael Findlay</name>
      <address>Clinical Trials New Zealand
Discipline of Oncology
Faculty of Medical and Health Sciences
University of Auckland
Private Bag 92019
Auckland</address>
      <phone>+64 9 3737599</phone>
      <fax>+64 9 3737927</fax>
      <email>mp.findlay@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>